13 results on '"Krüger, William"'
Search Results
2. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
- Author
-
Krüger, William H., Hirt, Carsten, Basara, Nadezda, Sayer, Herbert G., Behre, Gerhard, Fischer, Thomas, Grobe, Norbert, Maschmeyer, Georg, Neumann, Thomas, Schneidewind, Laila, Niederwieser, Dietger, Dölken, Gottfried, and Schmidt, Christian A.
- Subjects
- *
MANTLE cell lymphoma , *STEM cell transplantation , *NON-Hodgkin's lymphoma , *CELL transplantation , *OVERALL survival , *LYMPHOMA treatment , *THERAPEUTIC use of antineoplastic agents , *RESEARCH , *HOMOGRAFTS , *GRAFT versus host disease , *CLINICAL trials , *DOXORUBICIN , *RESEARCH methodology , *PROGNOSIS , *IMMUNOSUPPRESSION , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *QUALITY of life , *CYCLOPHOSPHAMIDE , *PREDNISONE , *LYMPHOMAS , *VINCRISTINE , *LONGITUDINAL method - Abstract
Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell transplantation (alloSCT) is associated with a higher early mortality, but can cure MCL. To investigate alloSCT for therapy of MCL, we conducted two prospective trials for de novo MCL (OSHO#74) and for relapsed or refractory MCL (OSHO#60). Fifteen and 24 patients were recruited, respectively. Induction was mainly R-DHAP alternating with R-CHOP. Conditioning was either Busulfan/Cyclophosphamide or Treosulfan/Fludarabin. Either HLA-identical siblings or matched-unrelated donors with not more than one mismatch were allowed. ATG was mandatory in mismatched or unrelated transplantation. Progression-free survival (PFS) was 62% and overall survival (OS) was 68% after 16.5-year follow-up. Significant differences in PFS and OS between both trials were not observed. Patients below 56 years and patients after myeloablative conditioning had a better outcome compared to patients of the corresponding groups. Nine patients have died between day +8 and 5.9 years after SCT. Data from 7 long-term surviving patients showed an excellent Quality-of-life (QoL) after alloSCT. AlloSCT for MCL delivers excellent long-term survival data. The early mortality is higher than after autoSCT; however, the survival curves after alloSCT indicate the curative potential of this therapy. AlloSCT is a standard of care for all feasible patients with refractory or relapsed MCL and should offer to selected patients with de novo MCL and a poor risk profile. For defining the position of alloSCT in the therapeutic algorithm of MCL therapy, a randomized comparison of autoSCT and alloSCT is mandatory. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.
- Author
-
Ni, Ming, Wang, Lei, Yang, Mingya, Neuber, Brigitte, Sellner, Leopold, Hückelhoven-Krauss, Angela, Schubert, Maria-Luisa, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Wuchter, Patrick, Chen, Bao-an, Eckstein, Volker, Krüger, William, Yerushalmi, Ronit, Beider, Katia, Nagler, Arnon, Müller-Tidow, Carsten, Dreger, Peter, and Schmitt, Michael
- Subjects
KILLER cells ,GRAFT versus host disease ,PHOTOPHORES ,HEMATOPOIETIC stem cells ,CYTOKINES - Abstract
CD56
bri natural killer (NK) cells play an important role in the pathogenesis of graft-vs. -host disease (GVHD) and immune defense in the early period after allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) as an immunomodulating therapy has been widely used for GVHD treatment. However, the mechanism of action of ECP still remains to be elucidated, particularly the influence of ECP on NK cells. Thirty-four patients with steroid-refractory/resistant acute GVHD (aGVHD) ≥ °II and moderate to severe chronic GVHD (cGVHD) received ECP therapy. Patient samples obtained during intensive and long-term treatment were analyzed. Immunomonitoring with respect to cell phenotype and function was performed on rested peripheral blood mononuclear cells (PBMCs) using multiparametric flow cytometry. NK activity in terms of cytokine release was analyzed by intracellular cytokine staining after co-culture with K562 cells. Moreover, the proliferative capacity of NK cells, CD4+ , and CD8+ T cells was determined by carboxyfluorescein succinimidyl ester (CFSE) staining. Clinically, 75% of aGVHD and 78% of cGVHD patients responded to ECP therapy. Moreover, our data show that aGVHD, cGVHD patients and healthy donors (HDs) present distinct NK patterns: aGVHD patients have a higher frequency of CD56bri NK subsets with stronger NKG2D and CD62L expression, while CD56− CD16+ NK cells with higher expression of CD57 and CD11b stand out as a signature population for cGVHD. ECP therapy could significantly decrease CD56bri CD16− NK cells with shifting the quality from a cytotoxic to a regulatory pattern and additionally mature CD56dim NK cells via upregulation of CD57 in complete responding aGVHD patients. Moreover, ECP could keep the anti-viral and anti-leukemic effects intact via maintaining specialized anti-viral/leukemic CD57+ NKG2C+ CD56dim NK cells as well as remaining the quality and quantity of cytokine release by NK cells. The proliferative capacity of effector cells remained constant over ECP therapy. In conclusion, ECP represents an attractive option to treat GVHD without compromising anti-viral/leukemic effects. Shaping of CD56bri NK cell compartment by downregulating the cytotoxic subset while upregulating the regulatory subset contributes to the mechanisms of ECP therapy in aGVHD. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
4. Ruxolitinib for Therapy of Graft-versus-Host Disease.
- Author
-
Neumann, Thomas, Schneidewind, Laila, Weigel, Martin, Plis, Andrzej, Vaizian, Rem, Schmidt, Christian A., and Krüger, William
- Subjects
RUXOLITINIB ,GRAFT versus host disease prevention ,PROTEIN-tyrosine kinase inhibitors ,DISEASE relapse prevention ,DIARRHEA ,ENZYME inhibitors ,GRAFT versus host disease ,HEMOLYTIC-uremic syndrome ,STEROIDS ,TREATMENT effectiveness ,SEVERITY of illness index ,THERAPEUTICS - Abstract
Objective. Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality. There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids. Furthermore, some patients may have contraindications against CNI or high-dose steroids. Efficacy of ruxolitinib against GvHD has been described recently. Methods. Ruxolitinib was used for treatment of acute or chronic GvHD in eight patients. The patients either needed intensification of therapy or had contraindications against use of CNI or high-dose steroids. Results. Supplementation of therapy in acute GvHD with severe diarrhea with ruxolitinib was unsuccessful. All these patients died from acute GvHD. Introduction of ruxolitinib into therapy and relapse prophylaxis in other patients was successful in 4/4 cases (CR=3, PR=1). Indications for ruxolitinib were contraindications against CNI due to aHUS in two cases and the need for steroid sparing in two other cases. None of these patients suffered from diarrhea at the initiation of ruxolitinib. Conclusion. Ruxolitinib was effective for therapy of acute and chronic GvHD in higher lines in patients without severe diarrhea. Ruxolitinib could replace successfully CNI and high-dose steroids. Further investigations are necessary to define the position of ruxolitinib in GvHD-therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus‐associated hemorrhagic cystitis following adult allogeneic stem cell transplantation—A systematic review.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Schmidt, Christian Andreas, and Krüger, William
- Subjects
INTRAVENOUS therapy ,INTRAVESICAL administration ,CYSTITIS ,HEMORRHAGE treatment ,POLYOMAVIRUS diseases ,BK virus ,STEM cell transplantation ,GRAFT versus host disease - Abstract
Abstract: Introduction: BK polyomavirus can lead to hemorrhagic cystitis (BKPyV‐HC) in allogeneic stem cell transplantation and therefore to increased morbidity. No causal therapy has been established yet. Cidofovir (CDV) is a nucleotide analog of cytosine that is active against various DNA viruses and it has been described for therapy of BKPyV‐HC using 2 admission routes: intravenous and intravesical. Methods: We performed a systematic review regarding the comparison of intravenous or intravesical cidofovir in the treatment of BKPyV‐HC following adult allogeneic stem cell transplantation. Since there is a lack of randomized controlled trials, we considered all kinds of studies for this review. Due to heterogeneity of the data, we were not able to perform a meta‐analysis, so the results are shown descriptively. Results: The literature search for primary studies yielded 232 results. Finally, 9 studies where considered which included a total of 189 adult patients with BKPyV‐HC after allogeneic stem cell transplantation. We could only identify retrospective studies for this review. A total of 172 patients received intravenous CDV, 17 patients received intravesical CDV, and 2 patients received CDV in both admission routes. In 68.0% of the cases, a complete response for intravenous CDV was documented and in 88.2% for intravesical CDV. Interestingly, no kidney toxicity was mentioned in intravesical CDV. 9.3% of the intravenously treated patients had renal failure. Conclusion: There is only weak evidence for the use of CDV. The intravesical admission route should be further investigated because of a good toxicity profile. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
- Author
-
Schroeder, Thomas, Rautenberg, Christina, Krüger, William, Platzbecker, Uwe, Bug, Gesine, Steinmann, Juliane, Klein, Stefan, Hopfer, Olaf, Nachtkamp, Kathrin, Kondakci, Mustafa, Geyh, Stefanie, Haas, Rainer, Germing, Ulrich, Bornhäuser, Martin, and Kobbe, Guido
- Subjects
MYELODYSPLASTIC syndromes treatment ,ACUTE myeloid leukemia treatment ,DECITABINE ,STEM cell transplantation ,GRAFT versus host disease ,SALVAGE therapy ,PUBLIC health ,THERAPEUTICS ,ANTINEOPLASTIC agents ,GRAFT versus host disease prevention ,THERAPEUTIC use of antimetabolites ,COMPARATIVE studies ,RED blood cell transfusion ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,RESEARCH methodology ,MEDICAL cooperation ,MYELODYSPLASTIC syndromes ,RESEARCH ,SURVIVAL analysis (Biometry) ,DISEASE relapse ,EVALUATION research ,ACUTE myeloid leukemia ,TREATMENT effectiveness ,DISEASE remission ,RETROSPECTIVE studies ,AZACITIDINE - Abstract
In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far. We retrospectively analyzed data of 36 patients with hematological (n = 35) or molecular relapse (n = 1) of acute myeloid leukemia (AML, n = 29) or myelodysplastic syndrome (MDS, n = 7) collected from 6 German transplant centers. Patients were treated with a median of 2 cycles DAC (range, 1 to 11). DAC was the first salvage therapy in 16 patients (44%), whereas 20 patients (56%) had previously received 1 to 5 lines of salvage therapy including 16 of them had been treated with Aza. In 22 patients (61%), a median of 2 DLI per patient (range, 1 to 5) was administered in addition to DAC. As a result, overall response rate was 25% including 6 complete remissions (CR, 17%) and 3 partial remissions (PR, 8%). Three patients within the first-line group achieved CR, while also 3 patients receiving DAC as second-line treatment reached CR including 2 patients with previous Aza failure. Median duration of CR was 10 months (range, 2 to 33) and no patient relapsed so far. The 2-year OS rate was 11% (± 6%) without any difference between first-line and pretreated patients. Incidence of acute and chronic graft-versus-host disease was 19 and 5%. Taken together, DAC exerts clinical efficacy in patients with AML or MDS relapsing after allo-SCT and is able to induce durable remissions in individual patients suggesting that DAC may be an alternative to Aza or even a second choice after Aza failure. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation.
- Author
-
Busemann, Christoph, Jülich, Andreas, Buchhold, Britta, Schmidt, Vanessa, Schneidewind, Laila, Pink, Daniel, Schmidt, Christian, Neumann, Thomas, and Krüger, William
- Subjects
STEM cell transplantation ,DYSPNEA ,GRAFT versus host disease ,PALLIATIVE treatment ,PATIENTS ,THERAPEUTICS - Abstract
Purpose: Allogeneic stem cell transplantation may cure approximately 50% of patients, however, a significant part of the other half might benefit from a high-quality palliative care medicine at the end of life. Somatic, psychic and spiritual needs of these patients may differ from those of patients suffering from incurable solid tumours and are not comprehensively evaluated so far. Methods: To address this question, data from charts of 123 patients who have died after allogeneic stem cell transplantation were extracted. In detail, the time line of the clinical course, the symptoms, the administered drugs and other applied procedures were analysed. Results: Approximately one half of the patients, who have died after stem cell transplantation, did not live more than 5 months. Two-thirds of patients died within 14 months after SCT. 28.5% of the patients could not be discharged after transplantation. However, a significant proportion had a low ECOG-score (0-1) prior to death, indicating a high degree of mobility. Major symptoms were weakness, fatigue and need for aid at daily activities. Severe pain, dyspnoea and obstipation, as known from patients suffering from advanced solid tumours, were rare. In consequence, use of opioids seemed to be less frequent than in patients with solid tumours. Measures of intensive care and i.v.-drug administration were applied to a significant proportion of patients. Conclusion: The present investigation indicates that the somatic, psychic and spiritual end-of-life-care after allogeneic stem cell transplantation could be optimised. A significant problem for the transplantation team seems to be the realisation of necessity to switch the curative concept into a palliative ambition. Requirements are a subsequent prospectively conducted investigation and an intensification of cooperation between transplant and palliative care teams. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?
- Author
-
Schneidewind, Laila, Neumann, Thomas, Knoll, Florian, Zimmermann, Kathrin, Smola, Sigrun, Schmidt, Christian andreas, and Krüger, William
- Subjects
BK virus ,ALEMTUZUMAB ,CYTOMEGALOVIRUSES ,ANTINEOPLASTIC agents ,JOHN Cunningham virus ,GRAFT versus host disease ,STEM cell transplantation ,THERAPEUTICS - Abstract
Background: The association of polyomaviruses BK and JC with other opportunistic infections and graft-versus-host disease (GvHD) in allogeneic stem cell transplantation is controversially discussed. Methods: We conducted a retrospective study of 64 adult patients who received their first allogeneic stem cell transplantation between March 2010 and December 2014; the follow-up time was 2 years. Results: Acute leukemia was the most frequent underlying disease (45.3%), and conditioning included myeloablative (67.2%) and nonmyeloablative protocols (32.8%). All patients received 10 mg of alemtuzumab on day -2 (20 mg in case of mismatch) as GvHD prophylaxis. Twenty-seven patients (41.5%) developed cytomegalovirus (CMV) reactivation. BKPyV-associated hemorrhagic cystitis was diagnosed in 10 patients (15.6%). Other opportunistic infections caused by viruses or protozoa occurred rarely (<10%). There was no association of BKPyV or JCPyV with CMV reactivation, Epstein-Barr virus reactivation, human herpes virus 6, or parvovirus B19 infection requiring treatment. There was a significant correlation of BKPyV-associated hemorrhagic cystitis with toxoplasmosis (p = 0.013). Additionally, there was a significant link of simultaneous BKPyV and JCPyV viruria with toxoplasmosis (p = 0.047). BKPyV and JCPyV were not associated with GvHD, relapse, or death. Conclusion: We found no association of BKPyV or JCPyV with viral infections or GvHD. Only the correlation of both polyomaviruses with toxoplasmosis was significant. This is a novel and interesting finding. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
- Author
-
Kröger, Nicolaus, Zabelina, Tatjana, Krüger, William, Renges, Helmut, Stute, Norbert, Dürken, Matthias, Graf von Finkenstein, Friedrich, Erttmann, Rolf, Kabisch, Hartmut, Schafhausen, Philipe, Jaburg, Nicole, Löliger, Cornelius, Zander, Axel R, Kröger, N, Zabelina, T, Krüger, W, Renges, H, Stute, N, Dürken, M, and Graf von Finkenstein, F
- Subjects
GRAFT versus host disease ,STEM cells ,TRANSPLANTATION of organs, tissues, etc. ,MYELOID leukemia ,GLOBULINS ,ORGAN donation - Abstract
To reduce the incidence of GvHD and the rate of graft failure in unrelated stem cell transplantation, we incorporate anti-thymocyte globulin in the preparative regimen in 98 patients with hematological or inherited storage disease. The median age was 32 years (range: 1-56) and 84 patients underwent transplantation from HLA-A,-B and DR identical donor, while in 14 patients the donor were mismatched either in HLA- A, -B or -DR locus. Only one patient with chronic myelocytic leukemia (CML) and blast crisis had a primary graft failure (1%). Grade II-IV acute GvHD occurred in 37 patients (37%), grade III/IV GvHD developed in 15 patients (15%). Chronic GvHD was observed in 29%, and only 12 patients had extensive GvHD (17%). After a median follow-up of 34 months (range, 9-90), the estimated overall survival at 3 years for all patients is 58% (CI 95%: 48%-68%), and the estimated disease-free survival at 3 years is 49% (CI 95%: 38%-60%). For patients with CML transplanted in first chronic phase or accelerated phase (n=40), the estimated overall survival at 3 years is 70% (CI 95%: 56%-84%), and the estimated disease-free survival at 3 years is 58% (CI 95%: 17%-85%). ATG in unrelated stem cell transplantation reduces the risk of severe acute and chronic GvHD and of graft failure without an obvious increase of severe infection. Further follow-up is mandatory to determine the incidence of late relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
10. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
- Author
-
Kröger, Nicolaus, Renges, Helmut, Krüger, William, Gutensohn, Kai, Löliger, Cornelius, Carrero, Isabel, Cortes, Lourdes, and Zander, Axel R.
- Subjects
GRANULOCYTES ,FILGRASTIM ,STEM cells ,HEMAPHERESIS ,GRAFT versus host disease ,TRANSPLANTATION of organs, tissues, etc. - Abstract
To evaluate the schedule dependency of granulocyte colony-stimulating factor (G-CSF) (filgrastim) for stem cell mobilization, we conducted a randomized comparison in 50 healthy donors, with one subcutaneous daily injection of 10 µg/kg G-CSF (n = 25) compared with twice injections daily of 5 µg/kg G-CSF (n = 25). The two groups were well balanced for age, body weight and sex. G-CSF application was performed on an out-patient basis and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were mild to moderate bone pain (88%), mild headache (72%), mild fatigue (48–60%) and nausea (8%) without differences between the two groups. The CD34
+ cell count in the first apheresis was 5·4 × 106 /kg donor weight (range 2·8–13·3) in the 2 × 5 µg/kg group compared with 4·0 × 106 /kg (range 0·4–8·8) in the 1 × 10µg/kg group (P = 0·007). The target of collecting > 3·0 × 106 CD34+ cells/kg donor weight with one apheresis procedure was achieved in 24/25 (96%) donors in the 2 × 5 µg/kg group and in 17/25 (68%) donors in the 1 × 10 µg/kg group. The target of collecting > 5·0 × 106 CD34+ cells/kg in the first apheresis was achieved in 64% in the 2 × 5µg/kg group, but in only 36% in the 1 × 10 µg/kg group. The progenitor cell assay for granulocyte–macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) was higher in the 2 × 5 µg/kg group than in the 1 × 10 µg/kg group (7·0 vs. 3·5 × 105 /kg, P = 0·01; 6·6 vs. 5·0 × 105 /kg; P = 0·1). Administering G-CSF (filgrastim) at a dosage of 5 µg/kg twice daily rather than 10 µg/kg once daily is recommended; this leads to a higher CD34+ cell yield and requires fewer apheresis procedures without increasing toxicity or cost. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
11. Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: Case study.
- Author
-
Lotze, Christian, Schüler, Frank, Krüger, William H., Hirt, Carsten, Kirsch, Michael, Vogelgesang, Silke, Schmidt, Christian A., and Dölken, Gotifried
- Subjects
HODGKIN'S disease ,LYMPHOMAS ,CENTRAL nervous system ,RADIOTHERAPY ,IMMUNOLOGY ,GRAFT versus host disease - Abstract
Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis. Graft-versus-leukemia effects (GvL) contribute substantially to eradication of hematological malignancies after allogeneic stem cell transplantation. Few data are available describing GvL activity within the brain. We report the case of a man allografted for peripheral NHL. On day +83 after transplantation a CNS relapse of the lymphoma occurred. The brain was irradiated with 44 Gy, anti-CD20 antibodies were given, and the immunosuppression was withdrawn. Subsequently, limited-stage, chronic graft-versus-host disease occurred. The lymphoma regressed completely, and the patient has been in continuous complete remission for 30 months. The favorable course suggests substantial contribution of immunomodulation to excellent outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
12. Epstein–Barr virus reactivation after allogeneic stem cell transplantation without lymph node enlargement.
- Author
-
Krüger, William, Schüler, Frank, Lotze, Christian, Schwesinger, Günther, Mentel, Renate, Busemann, Christoph, and Dölken, Gottfried
- Subjects
- *
LETTERS to the editor , *GRAFT versus host disease - Abstract
Presents a letter to the editor reporting a case of Epstein-Barr virus reactivation after allogeneic stem cell transplantation without lymph node enlargement.
- Published
- 2005
- Full Text
- View/download PDF
13. Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells.
- Author
-
Ni, Ming, Wang, Lei, Ding, Yuntian, Gong, Wenjie, Wang, Sanmei, Neuber, Brigitte, Schubert, Maria-Luisa, Sauer, Tim, Hückelhoven-Krauss, Angela, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Eckstein, Volker, Wang, Jishi, Krüger, William, Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael, and Schmitt, Anita
- Subjects
- *
GRANULOCYTES , *GRANULOCYTE-macrophage colony-stimulating factor , *IMMUNE checkpoint proteins , *T cells , *GRAFT versus host disease , *IMMUNOLOGICAL tolerance - Abstract
• ECP was able to increase Tfh cells to ameliorate GvHD. • Upregulation of Th22 cells was observed in aGvHD patients with CR. • Tim-3 expression was downregulated on effector T cells by ECP. • ECP shows immunomodulatory effects in GvHD setting. Extracorporeal photopheresis (ECP), a personalized cellular immunotherapy, constitutes a promising treatment for steroid-refractory/-resistant graft-versus-host disease (SR-GvHD), with encouraging clinical response rates. To further investigate its mechanism of action, ECP's effects on T helper (Th) cells as well as on expression of immune checkpoint (PD-1 and Tim-3) and apoptotic (Fas receptor [FasR]) molecules were investigated in 27 patients with SR-GvHD. Our data show that GvHD patients had significantly higher levels of Th2, Th17, Th22 and granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive Th (ThG) cells and clearly lower levels of T follicular helper (Tfh) cells, including Th1- and Th2-like cells, compared with healthy donors. ECP therapy for GvHD was effective through the modulation of different Th subsets: increases of Th22 (1.52-fold) and Tfh cells (1.48-fold) in acute GvHD (aGvHD) and increases of Th2-like Tfh cells (1.74-fold) in chronic GvHD (cGvHD) patients were associated with clinical response. Expression of FasR was further upregulated in CD4+CD8+ T cells. Additionally, Tim-3–expressing effector T cells associated with the severity of GvHD were reduced. Taken together, these data show that ECP therapy exerts immunomodulatory effects by promoting a balanced immune reconstitution and inducing immune tolerance. Therefore it represents an attractive option for the treatment of GvHD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.